:
Multiple Myeloma (MM) is the third most common and deadly hematological malignancy, which is
characterized by a progressive monoclonal proliferation within the bone marrow. MM is cytogenetically heterogeneous
with numerous genetic and epigenetic alterations, which lead to a wide spectrum of signaling pathways and cell cycle
checkpoint aberrations. MM symptoms can be attributed to CRAB features (hyperCalcemia, Renal failure, Anemia and
Bone lesion), which profoundly affect both the Health-Related Quality of Life (HRQoL) and the life expectancy of
patients. Despite all enhancement and improvement in therapeutic strategies, MM is almost incurable, and patients faced
to this disease eventually relapse. Curcumin is an active and nontoxic phenolic compound, isolated from the rhizome of
Curcuma longa L. It has been widely studied and has a confirmed broad range of therapeutic properties, especially anticancer activity, including anti-proliferation, anti-angiogenesis, antioxidant and anti-mutation activities. Curcumin induces
apoptosis in cancerous cells and prevents Multidrug Resistance (MDR). Growing evidence concerning the therapeutic
properties of curcumin caused a pharmacological impact on MM. It is confirmed that curcumin interferes with various
signaling pathways and cell cycle checkpoints, and with oncogenes. In this paper, we summarized the anti-MM effects of
curcumin.